1. Contemporary survival of adults with congenital heart disease
- Author
-
Barbara J.M. Mulder, T.C. Konings, Teun van der Bom, Folkert J. Meijboom, Berto J. Bouma, Arie P.J. van Dijk, Petronella G. Pieper, Aeilko H. Zwinderman, Hubert W. Vliegen, Cardiovascular Centre (CVC), Cardiology, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, Epidemiology and Data Science, and ICaR - Heartfailure and pulmonary arterial hypertension
- Subjects
Male ,Pediatrics ,Time Factors ,SURGERY ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,BELGIUM ,Kaplan-Meier Estimate ,Severity of Illness Index ,Risk Factors ,Odds Ratio ,Prospective Studies ,Registries ,Survivors ,Young adult ,Prospective cohort study ,Non-U.S. Gov't ,POPULATION ,Netherlands ,education.field_of_study ,Research Support, Non-U.S. Gov't ,Age Factors ,TIME-SCALE ,Middle Aged ,Prognosis ,PREVALENCE ,Population study ,Female ,Cardiology and Cardiovascular Medicine ,BURDEN ,Adult ,Heart Defects, Congenital ,medicine.medical_specialty ,SEX-DIFFERENCES ,Population ,Research Support ,Young Adult ,Severity of illness ,medicine ,Journal Article ,Humans ,education ,Survival analysis ,Proportional Hazards Models ,Proportional hazards model ,business.industry ,MORTALITY ,Odds ratio ,LIFE ,Logistic Models ,Linear Models ,business ,FOLLOW-UP - Abstract
Item does not contain fulltext BACKGROUND: Survival data that are applicable to the current population of adults with congenital heart disease (CHD) are not available. OBJECTIVES: Using an alternative survival analysis with age as the primary time scale, we assessed the contemporary survival of adult patients with CHD. METHODS: Survival was assessed using prospective data of the national registry of adult patients with CHD of the Netherlands. Survival was stratified by severity and lesion, and compared with a standardised general population. RESULTS: Mean age at inclusion was 37 years, and 49% of the study population was male. During a cumulative prospective follow-up of 90 270 patient-years in 14 327 patients, 535 deaths occurred. Median survival was 53.4 (95% CI 49.9 to 60.7), 75.4 (95% CI 72.9 to 79.1) and 84.1 (95% CI 81.9 to 87.0) years for patients with severe, moderate and mild lesions, respectively. Survival of most patients with mild lesions did not differ from the general population, while, as expected, survival of patients with severe and moderate lesions was substantially lower (
- Published
- 2015
- Full Text
- View/download PDF